Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2010, Pages

  Des Guetz, Gaëtan ^a   Uzzan, Bernard ^a   Morere, Jean Francois ^a   Perret, Gerard ^a   Nicolas, Patrick ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 77950877745     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007046.pub2     Document Type: Article

References (14)

1. André T. Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1. J Clin Oncol 2007;25(24):3732-8.
2. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005;23(34):8671-8678.
3. Ito K, Kato T, Koike A, Miura K, Yamaguchi A, Sakou T, Takagi H. Optimum duration of oral adjuvant chemotherapy of HCFU for colorectal cancer; review of 5-year follow-up. Anticancer Res 2000;20(6C):4681-6.
4. Nakamura T, Ohno M, Tabuchi Y, Kamigaki T, Fujii H, Yamagishi H, Kuroda Y, Kansai Carmofur Study Group. Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III. Int J Oncol 2001;19(2):291-8.
5. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16(1):295-300.
6. Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Oates JR. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005;16(4):549-557.
7. Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006;24(15):2368-2375.
8. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003;21(15):2896-2903.
9. Bleiberg H, Rougier P, Wilke HJ. Management of Colorectal Cancer. London: Martin Dunitz, 1998.
10. Chau I, Cunningham D. Adjuvant therapy in colon cancer - what, when and how?. Ann Oncol 2006;17(9):1347-1359.
11. Dencausse Y, Hartung G, Sturm J, Kopp-Schneider A, Hagmuller E, Wojatschek C, Lindemann H, Fritze D, Queisser W. Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkologie 2002;25(5):426-30.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-188.
13. Gibson TB, Grothey A. Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?. Clin Colorectal Cancer 2006;6(3):196-201.
14. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003;88(12):1859-65.